Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1417-1419, 2003; 10.1373/49.8.1417
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, E.
Right arrow Articles by Beilby, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, E.
Right arrow Articles by Beilby, J.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2003;49:1417-1419.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Sample Preparation in Patients Receiving Uric Acid Oxidase (Rasburicase) Therapy

EeMun Lim1, Peter Bennett1 and John Beilby1,a

1 Department of Clinical Biochemistry, PathCentre, The Western Australian Centre for, Pathology and Medical Research, Hospital Avenue, Nedlands, Western Australia 6009 Australia

aAddress correspondence to this author at: Department of Clinical Biochemistry, PathCentre, Locked Bag 2009, Nedlands, Western Australia 6909, Australia. Fax: 61-8-9346-3882; e-mail: john.beilby@health.wa.gov.au.

The first 20% of the full text of this article appears below.


To the Editor:

With the advances in medicine and the development of newer therapeutic agents, the laboratorian needs to be constantly aware of the potential analytical interferences from these medications. Here we demonstrate a potential analytical interference with a case report of a patient who received the recombinant uric acid oxidase Rasburicase (Sanofi-Synthelabo) and the sample handling requirements for uric acid analysis. Rasburicase is a potent uricolytic agent that catalyzes the enzymatic oxidation of uric acid to allantoin, a water soluble metabolite that is readily excreted by the kidney (1). It is used in the treatment and prevention of hyperuricemia, predominantly in patients with hematologic malignancies (1)(2)(3)(4)(5). The half-life of Rasburicase is estimated to be between 16 and 22 h (2).

A 28-year-old man presented with ascites to the emergency department at Sir Charles Gairdner Hospital, a tertiary teaching hospital in Western Australia. The patient was subsequently diagnosed with B-cell non-Hodgkin lymphoma 7 days postadmission. The day before commencement of the patient’s scheduled chemotherapy (day 8 of admission), he developed tumor lysis syndrome. The patient had severe metabolic acidosis (9 mmol/L plasma bicarbonate; reference interval, 22–32 . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
V. Stove, B. Wuyts, and J. Delanghe
Perchloric Acid Treatment To Stabilize Uric Acid Concentrations in Blood Samples of Patients Receiving Uric Acid Oxidase (Rasburicase) Therapy
Clin. Chem., February 1, 2007; 53(2): 369 - 370.
[Full Text] [PDF]

Home page
 IEICE Trans FundamentalsHome page
J.-F. QIAN, L.-N. ZHANG, and S.-X. ZHU
Constacyclic and Cyclic Codes over F2 + uF2 + u2F2
IEICE Trans A: Fundamentals, June 1, 2006; E89-A(6): 1863 - 1865.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.